AP741A - Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring. - Google Patents

Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring. Download PDF

Info

Publication number: AP741A
Authority: AP; ARIPO
Prior art keywords: dichloro; cyclopentanediol; hydroxymethyl; benzimidazol; compound
Prior art date: 1994-09-09

Application number

APAP/P/1997/000940A

Other languages

English (en)

Other versions

AP9700940A0 (en

Inventor

Leroy B Townsend

Susan Mary Daluge

Original Assignee

The Wellcome Foundation Ltd

Univ Michigan Regents

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-09

Filing date

1995-09-11

Publication date

1999-04-26

1994-09-09 Priority claimed from US08/304,006 external-priority patent/US5534535A/en

1995-09-11 Application filed by The Wellcome Foundation Ltd, Univ Michigan Regents filed Critical The Wellcome Foundation Ltd

1997-04-30 Publication of AP9700940A0 publication Critical patent/AP9700940A0/xx

1999-04-26 Application granted granted Critical

1999-04-26 Publication of AP741A publication Critical patent/AP741A/en

Links

230000000840 anti-viral effect Effects 0.000 title abstract description 3
125000002837 carbocyclic group Chemical group 0.000 title abstract description 3
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
229940127073 nucleoside analogue Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 127
-1 isopropylamino Chemical group 0.000 claims abstract description 25
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 15
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
208000002672 hepatitis B Diseases 0.000 claims abstract description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
241000700721 Hepatitis B virus Species 0.000 claims description 21
229910052736 halogen Inorganic materials 0.000 claims description 20
150000002367 halogens Chemical class 0.000 claims description 20
238000000034 method Methods 0.000 claims description 17
238000011282 treatment Methods 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
208000036142 Viral infection Diseases 0.000 claims description 8
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 8
230000009385 viral infection Effects 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 4
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
206010011831 Cytomegalovirus infection Diseases 0.000 claims description 4
229910052740 iodine Inorganic materials 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
206010019972 Herpes viral infections Diseases 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
FZORJBVDVIFUMJ-FOLSVITISA-N (1s,2r,3s,5s)-3-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1C[C@@H](CO)[C@H](O)[C@@H]1O FZORJBVDVIFUMJ-FOLSVITISA-N 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000006317 cyclopropyl amino group Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
YQKSRXKUVVMWPH-UHFFFAOYSA-N 1-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound OCC1(O)CCCC1O YQKSRXKUVVMWPH-UHFFFAOYSA-N 0.000 claims 2
ZBAXTIFHKIGLEJ-UHFFFAOYSA-N 3-(hydroxymethyl)cyclopentan-1-ol Chemical compound OCC1CCC(O)C1 ZBAXTIFHKIGLEJ-UHFFFAOYSA-N 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
241000701022 Cytomegalovirus Species 0.000 abstract description 7
230000000694 effects Effects 0.000 abstract description 7
241001529453 unidentified herpesvirus Species 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 82
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 66
239000000203 mixture Substances 0.000 description 66
239000000243 solution Substances 0.000 description 60
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
239000004480 active ingredient Substances 0.000 description 45
239000003039 volatile agent Substances 0.000 description 43
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
239000007787 solid Substances 0.000 description 37
239000000741 silica gel Substances 0.000 description 36
229910002027 silica gel Inorganic materials 0.000 description 36
238000009472 formulation Methods 0.000 description 34
239000003921 oil Substances 0.000 description 34
239000000843 powder Substances 0.000 description 34
235000019198 oils Nutrition 0.000 description 33
238000001819 mass spectrum Methods 0.000 description 29
238000005481 NMR spectroscopy Methods 0.000 description 28
235000019441 ethanol Nutrition 0.000 description 28
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 22
238000005160 1H NMR spectroscopy Methods 0.000 description 20
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 17
208000015181 infectious disease Diseases 0.000 description 17
238000010828 elution Methods 0.000 description 16
238000001704 evaporation Methods 0.000 description 16
230000008020 evaporation Effects 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000000523 sample Substances 0.000 description 15
239000002904 solvent Substances 0.000 description 15
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
239000011521 glass Substances 0.000 description 14
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
239000013078 crystal Substances 0.000 description 13
239000000047 product Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
241000700605 Viruses Species 0.000 description 11
125000003118 aryl group Chemical group 0.000 description 11
150000002148 esters Chemical class 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
238000010992 reflux Methods 0.000 description 11
229920006395 saturated elastomer Polymers 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
150000003839 salts Chemical class 0.000 description 10
238000003756 stirring Methods 0.000 description 10
239000003826 tablet Substances 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000008101 lactose Substances 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
229940069328 povidone Drugs 0.000 description 8
229910052938 sodium sulfate Inorganic materials 0.000 description 8
235000011152 sodium sulphate Nutrition 0.000 description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
239000012043 crude product Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
235000019256 formaldehyde Nutrition 0.000 description 6
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
229910000029 sodium carbonate Inorganic materials 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
UYWWLYCGNNCLKE-UHFFFAOYSA-N 2-pyridin-4-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=CC=NC=C1 UYWWLYCGNNCLKE-UHFFFAOYSA-N 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
241000701085 Human alphaherpesvirus 3 Species 0.000 description 5
241000701027 Human herpesvirus 6 Species 0.000 description 5
206010037660 Pyrexia Diseases 0.000 description 5
241000700584 Simplexvirus Species 0.000 description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
235000019253 formic acid Nutrition 0.000 description 5
238000011321 prophylaxis Methods 0.000 description 5
239000002002 slurry Substances 0.000 description 5
239000008259 solid foam Substances 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 4
229940093499 ethyl acetate Drugs 0.000 description 4
239000006260 foam Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
239000008187 granular material Substances 0.000 description 4
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 4
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
239000012452 mother liquor Substances 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
229940080313 sodium starch Drugs 0.000 description 4
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
239000000829 suppository Substances 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
VTCHZFWYUPZZKL-UHNVWZDZSA-N (1s,4r)-4-azaniumylcyclopent-2-ene-1-carboxylate Chemical compound [NH3+][C@@H]1C[C@H](C([O-])=O)C=C1 VTCHZFWYUPZZKL-UHNVWZDZSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 3
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
208000010201 Exanthema Diseases 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000701024 Human betaherpesvirus 5 Species 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
239000007868 Raney catalyst Substances 0.000 description 3
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
229910000564 Raney nickel Inorganic materials 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
YFPCLQKFNXUAAK-UHFFFAOYSA-N cyclopentyl acetate Chemical compound CC(=O)OC1CCCC1 YFPCLQKFNXUAAK-UHFFFAOYSA-N 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
201000005884 exanthem Diseases 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
239000012285 osmium tetroxide Substances 0.000 description 3
229910000489 osmium tetroxide Inorganic materials 0.000 description 3
BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
206010037844 rash Diseases 0.000 description 3
238000007711 solidification Methods 0.000 description 3
230000008023 solidification Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
201000006082 Chickenpox Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
206010046980 Varicella Diseases 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
239000003708 ampul Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
UGZJWYZDAWVHFC-UHFFFAOYSA-N cyclopent-3-en-1-ylmethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1CC=CC1 UGZJWYZDAWVHFC-UHFFFAOYSA-N 0.000 description 2
UYDJAHJCGZTTHB-UHFFFAOYSA-N cyclopentane-1,1-diol Chemical compound OC1(O)CCCC1 UYDJAHJCGZTTHB-UHFFFAOYSA-N 0.000 description 2
231100000676 disease causative agent Toxicity 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000013160 medical therapy Methods 0.000 description 2
239000000155 melt Substances 0.000 description 2
229940095102 methyl benzoate Drugs 0.000 description 2
238000000465 moulding Methods 0.000 description 2
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
239000006072 paste Substances 0.000 description 2
125000005010 perfluoroalkyl group Chemical group 0.000 description 2
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000011775 sodium fluoride Substances 0.000 description 2
235000013024 sodium fluoride Nutrition 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229910052717 sulfur Chemical group 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
MDOLBEKYSKXKMQ-URLXBVOPSA-N (1s,2r,3r,5r)-3-(4,5-dichloro-2-nitroanilino)-5-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound O[C@H]1[C@@H](O)[C@@H](CO)C[C@H]1NC1=CC(Cl)=C(Cl)C=C1[N+]([O-])=O MDOLBEKYSKXKMQ-URLXBVOPSA-N 0.000 description 1
SFUVLEGIZGPPNN-UHFFFAOYSA-N (2-pyridin-2-ylacetyl) 2-pyridin-2-ylacetate Chemical compound C=1C=CC=NC=1CC(=O)OC(=O)CC1=CC=CC=N1 SFUVLEGIZGPPNN-UHFFFAOYSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
IHLRGGLJGGTPCY-HWKANZROSA-N (e)-hept-5-en-3-one Chemical compound CCC(=O)C\C=C\C IHLRGGLJGGTPCY-HWKANZROSA-N 0.000 description 1
HHLCSFGOTLUREE-UHFFFAOYSA-N 1,2,3-trichloro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Cl)C(Cl)=C1 HHLCSFGOTLUREE-UHFFFAOYSA-N 0.000 description 1
IBRBMZRLVYKVRF-UHFFFAOYSA-N 1,2,4-trichloro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Cl)C=C1Cl IBRBMZRLVYKVRF-UHFFFAOYSA-N 0.000 description 1
AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
BPPVUXSMLBXYGG-UHFFFAOYSA-N 4-[3-(4,5-dihydro-1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1h-pyrazol-3-one Chemical compound CC1=C(C(=O)C=2C(N(C)NC=2)=O)C=CC(S(C)(=O)=O)=C1C1=NOCC1 BPPVUXSMLBXYGG-UHFFFAOYSA-N 0.000 description 1
IPRDZAMUYMOJTA-UHFFFAOYSA-N 5,6-dichloro-1h-benzimidazole Chemical compound C1=C(Cl)C(Cl)=CC2=C1NC=N2 IPRDZAMUYMOJTA-UHFFFAOYSA-N 0.000 description 1
QZZGLNTXJCNQTI-UHFFFAOYSA-N 6-(azetidin-1-yl)-5-bromo-1h-pyrimidine-2,4-dione Chemical compound OC1=NC(O)=C(Br)C(N2CCC2)=N1 QZZGLNTXJCNQTI-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241001091551 Clio Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
201000005866 Exanthema Subitum Diseases 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000005794 Hairy Leukoplakia Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
206010024971 Lower respiratory tract infections Diseases 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
206010037898 Rash vesicular Diseases 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
UXKZFJDNFBNQHE-NTSWFWBYSA-N [(1r,4s)-4-aminocyclopent-2-en-1-yl]methanol Chemical compound N[C@H]1C[C@@H](CO)C=C1 UXKZFJDNFBNQHE-NTSWFWBYSA-N 0.000 description 1
AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
238000002832 anti-viral assay Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
206010016165 failure to thrive Diseases 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
229960005102 foscarnet Drugs 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
150000004688 heptahydrates Chemical class 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
VKTOBGBZBCELGC-UHFFFAOYSA-M methyl(triphenoxy)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1O[P+](OC=1C=CC=CC=1)(C)OC1=CC=CC=C1 VKTOBGBZBCELGC-UHFFFAOYSA-M 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
208000004141 microcephaly Diseases 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical group N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
150000004072 triols Chemical class 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

APAP/P/1997/000940A 1994-09-09 1995-09-11 Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring. AP741A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/304,006 US5534535A (en)	1992-03-09	1994-09-09	Therapeutic nucleosides
PCT/US1995/011366 WO1996007646A1 (en)	1994-09-09	1995-09-11	Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring

Publications (2)

Publication Number	Publication Date
AP9700940A0 AP9700940A0 (en)	1997-04-30
AP741A true AP741A (en)	1999-04-26

Family

ID=23174626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1997/000940A AP741A (en)	1994-09-09	1995-09-11	Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring.

Country Status (17)

Country	Link
EP (1)	EP0779885A1 (is)
JP (1)	JPH10505092A (is)
CN (1)	CN1164855A (is)
AP (1)	AP741A (is)
AU (1)	AU3692895A (is)
BR (1)	BR9508826A (is)
CA (1)	CA2199502A1 (is)
CZ (1)	CZ71297A3 (is)
FI (1)	FI970959A7 (is)
HU (1)	HUT77440A (is)
IS (1)	IS4436A (is)
NO (1)	NO971070L (is)
NZ (1)	NZ294095A (is)
OA (1)	OA10601A (is)
PL (1)	PL319440A1 (is)
SK (1)	SK29197A3 (is)
WO (1)	WO1996007646A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5912356A (en) *	1995-09-11	1999-06-15	Glaxo Wellcome Inc.	Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
GB9600142D0 (en) *	1996-01-05	1996-03-06	Wellcome Found	Chemical compounds
US6413938B1 (en)	1997-02-13	2002-07-02	The Regents Of The University Of Michigan	Benzimidazole derivatives for the treatment of viral infections
AU744176B2 (en)	1997-07-30	2002-02-14	Glaxo Group Limited	Lyxofuranosyl benzimidazoles as antiviral agents
US6770666B2 (en)	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
CZ20013424A3 (cs)	1999-12-27	2002-02-13	Japan Tobacco Inc.	Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
GB0008939D0 (en)	2000-04-11	2000-05-31	Glaxo Group Ltd	Process for preparing substituted benzimidazole compounds
AR035543A1 (es) *	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CN1834090B (zh) *	2005-03-18	2011-06-29	中国科学院上海药物研究所	苯并咪唑类化合物、其制备方法以及用途
EP2540727B1 (en)	2007-08-02	2018-07-25	Millennium Pharmaceuticals, Inc.	Sulfamoylating reagent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993018009A1 (en) *	1992-03-09	1993-09-16	The Wellcome Foundation Limited	Antiviral nucleoside analogues

1995
- 1995-09-11 JP JP8509679A patent/JPH10505092A/ja not_active Ceased
- 1995-09-11 HU HU9702310A patent/HUT77440A/hu unknown
- 1995-09-11 AU AU36928/95A patent/AU3692895A/en not_active Abandoned
- 1995-09-11 SK SK291-97A patent/SK29197A3/sk unknown
- 1995-09-11 AP APAP/P/1997/000940A patent/AP741A/en active
- 1995-09-11 CZ CZ97712A patent/CZ71297A3/cs unknown
- 1995-09-11 WO PCT/US1995/011366 patent/WO1996007646A1/en not_active Ceased
- 1995-09-11 CN CN95196148A patent/CN1164855A/zh active Pending
- 1995-09-11 PL PL95319440A patent/PL319440A1/xx unknown
- 1995-09-11 EP EP95934402A patent/EP0779885A1/en not_active Withdrawn
- 1995-09-11 NZ NZ294095A patent/NZ294095A/en unknown
- 1995-09-11 CA CA002199502A patent/CA2199502A1/en not_active Abandoned
- 1995-09-11 BR BR9508826A patent/BR9508826A/pt not_active Application Discontinuation
1997
- 1997-03-06 FI FI970959A patent/FI970959A7/fi unknown
- 1997-03-07 OA OA60973A patent/OA10601A/en unknown
- 1997-03-07 IS IS4436A patent/IS4436A/is unknown
- 1997-03-07 NO NO971070A patent/NO971070L/no unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993018009A1 (en) *	1992-03-09	1993-09-16	The Wellcome Foundation Limited	Antiviral nucleoside analogues

Also Published As

Publication number	Publication date
JPH10505092A (ja)	1998-05-19
SK29197A3 (en)	1997-10-08
PL319440A1 (en)	1997-08-04
MX9701789A (es)	1997-10-31
CZ71297A3 (en)	1997-08-13
AU3692895A (en)	1996-03-27
CN1164855A (zh)	1997-11-12
EP0779885A1 (en)	1997-06-25
FI970959A0 (fi)	1997-03-06
NO971070L (no)	1997-05-07
WO1996007646A1 (en)	1996-03-14
IS4436A (is)	1997-03-07
AP9700940A0 (en)	1997-04-30
HUT77440A (hu)	1998-04-28
CA2199502A1 (en)	1996-03-14
FI970959A7 (fi)	1997-05-06
BR9508826A (pt)	1997-09-30
NZ294095A (en)	1998-08-26
OA10601A (en)	2002-09-03
NO971070D0 (no)	1997-03-07

Publication	Publication Date	Title
OA10610A (en)	2002-09-06	Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists.
EP0630368B1 (en)	1998-09-09	Antiviral nucleoside analogues
US5840990A (en)	1998-11-24	Intermediates to carbocyclic nucleosides
FI117629B (fi)	2006-12-29	Terapeuttisia yhdisteitä
KR101876240B1 (ko)	2018-08-02	벤즈이미다졸 호흡기 세포융합 바이러스 억제제
US5399580A (en)	1995-03-21	Therapeutic nucleosides-uses
PT90973B (pt)	1994-11-30	Peocesso para a preparacao de nucleosidos terapeuticos analogos da purina e de composicoes farmaceuticas que os contem
EP3331895A1 (en)	2018-06-13	Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EP0779885A1 (en)	1997-06-25	Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
US5998398A (en)	1999-12-07	2-amino-5,6-dichlorobenzimidazole derivatives having antiviral activity
US5912356A (en)	1999-06-15	Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
MXPA97001789A (en)	1998-07-03	Antiviral nucleosid analogues containing a substitute benzymidazole base united to a carbocicl ring
HK1003941B (en)	2004-02-06	Therapeutic nucleosides
HK1185065A (en)	2014-02-07	Benzimidazole respiratory syncytial virus inhibitors